Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 380 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Antipsychotic Clear all

Conditions: Social Anxiety Disorder
Interventions: quetiapine; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Alzheimer Disease, Dementia, Prescribing, Off-Label
Interventions: Overprescribing letter to attributed physician, Placebo letter to attributed physician; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: Not listed
Enrollment: 336,460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Boston, Massachusetts • Cambridge, Massachusetts • New York, New York

Conditions: Borderline Personality Disorder
Interventions: Rexulti, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Adverse Effect of Other Antipsychotics and Neuroleptics, Insulin Resistance
Interventions: olanzapine, placebo; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 21 Years to 45 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Bipolar Disorder, Alcoholism, Alcohol Abuse
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Schizophrenia
Interventions: Risperidone, Olanzapine; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Bipolar Disorder
Interventions: Divalproex Sodium, risperidone; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 10 Years to 20 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 3
States / cities: Chicago, Illinois

Conditions: Insulin Resistance, Diabetes Mellitus
Interventions: Olanzapine 10 mg po qhs for 3 days, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 30 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Schizophrenia
Interventions: PF-03463275, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 37
States / cities: Cerritos, California • Chula Vista, California • Escondido, California + 26 more

Conditions: Schizophrenia and Disorders With Psychotic Features
Interventions: Cognitive Behavioral Group Therapy, Cognitive remediation, Medications, MFG, Assertive case management, Treatment as Usual in the community; Behavioral · Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 16 Years to 45 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Bipolar Disorder Depression
Interventions: ABX-002; Drug
Lead sponsor: Autobahn Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 14
States / cities: Walnut Creek, California • Cromwell, Connecticut • Hartford, Connecticut + 10 more

Conditions: Alzheimer Disease, Dementia, Caregiver Burnout
Interventions: STAR-C-VTF, Control; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 65 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Schizophrenia
Interventions: Paliperidone ER, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 10
States / cities: Cerritos, California • Fountain Valley, California • San Diego, California + 7 more

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder, Autism Spectrum Disorders
Interventions: Metformin; Drug
Lead sponsor: Cambridge Health Alliance; Other
Eligibility: 10 Years to 18 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Medford, Massachusetts

Conditions: Stuttering
Interventions: Asenapine; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Orange, California

Conditions: Glioblastoma Multiforme
Interventions: Combination Drug Therapy; Drug
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Asthma, Mental Health, Pain
Interventions: provider feedback, patient intervention, Process-level; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: Not listed
Enrollment: 174,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Bipolar Disorder, Medication Adherence, Medication Non Adherence
Interventions: Abilify Maintena, Customized Adherence Enhancement (CAE); Drug · Behavioral
Lead sponsor: Martha Sajatovic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Behavioral and Psychiatric Symptoms of Dementia
Interventions: Not listed
Lead sponsor: Tabula Rasa HealthCare; Industry
Eligibility: 55 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Moorestown, New Jersey

Conditions: Schizophrenia, Impaired Cognition
Interventions: EVP-6124, Placebo; Drug
Lead sponsor: FORUM Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 767 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 49
States / cities: Phoenixville, Arizona • Little Rock, Arkansas • Cerritos, California + 46 more

Conditions: Schizophrenia
Interventions: perphenazine, olanzapine, quetiapine, risperidone, ziprasidone, clozapine, fluphenazine decanoate; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 54
States / cities: Chula Vista, California • Los Angeles, California • Orange, California + 45 more

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar I Disorder, Bipolar II, Bipolar NOS(Not Otherwise Specified), Psychotic Disorder Not Otherwise Specified, Autism Spectrum Disorder
Interventions: Betahistine, Placebo Oral Tablet; Drug
Lead sponsor: Nathan Kline Institute for Psychiatric Research; Other
Eligibility: 18 Years to 59 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Orangeburg, New York

Conditions: Bipolar I Disorder, Depression
Interventions: Cariprazine, Aripiprazole/Escitalopram combination, Quetiapine, Lurasidone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2,726 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 17
States / cities: Birmingham, Alabama • Bloomington, Indiana • Baltimore, Maryland + 13 more

Conditions: Schizophrenia, Negative Symptoms in Schizophrenia
Interventions: Study App; Device
Lead sponsor: Click Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Quetiapine in Social Anxiety Disorder

The Effect of De-Prescribing Antipsychotics on Health and Quality of Life for People With Dementia

Brexpiprazole in Borderline Personality Disorder

Molecular Mechanisms of Antipsychotic-induced Insulin Resistance

Aripiprazole for Bipolar Disorder and Alcohol Use Disorder

Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI

Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar

A Crossover Study of the Acute Effects of Olanzapine in Healthy Volunteers

A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia

Specialized Treatment Early in Psychosis (STEP)

Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults

STAR Caregivers - Virtual Training and Follow-up

A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients

An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.

A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering

Cancer Stem Cell High-Throughput Drug Screening Study

Electronic Pharmacotherapy Risk Management

CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)

The Use of Antipsychotics in the Program of All-inclusive Care for the Elderly (PACE)

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

CATIE- Schizophrenia Trial

Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain

Sequential Multiple Assignment Randomized Trial for Bipolar Depression

An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia